News
Video streaming could help emergency medical services
Innovative technology enabling ambulance service dispatchers to view footage from the scene of trauma incidents, via video live streaming from mobile phones, is feasible to implement and evaluate, a new study led by the University of Surrey reveals. Such technology, used via 999 callers’ smartphones, could aid emergency services decision-making about how many and what type of emergency medical personnel and vehicles to send to major trauma incidents. Building on their previous work evaluating the
use of GoodSAM Instant-On-Scene technology, Surrey researchers, in collaboration with Air Ambulance Charity Kent, Surrey and Sussex (KSS), London Ambulance Service (LAS) and South East Coast Ambulance Service (SECAmb), conducted the first randomised controlled trial in the world to evaluate the feasibility of implementing and evaluating the technology in this emergency setting and whether its use would be acceptable to members of the public. Professor Richard Lyon MBE, Professor of Pre- Hospital Emergency Care at the University of Surrey
and Director of Research and Innovation at Air Ambulance Charity Kent, Surrey, Sussex, said: “Giving dispatchers eyes on the ground could be game- changing in helping them dispatch the appropriate response to major trauma incidents. Air ambulance services are important, scarce and expensive resources that must be tasked accurately to those patients who need them most. “What we have found is live video streaming from 999 callers is feasible to implement, acceptable, and easy to use for both callers and dispatchers. More research is needed to understand the impact that live streaming has on dispatch decisions, and whether it can improve the speed and accuracy of ambulance dispatch. We also found it challenging to recruit 999 callers to the study and need to work with members of the public to overcome this challenge for future research, as their insight is invaluable.” The study was published in the Scandinavian
Journal of Trauma, Resuscitation and Emergency Medicine and was funded by the National Institute for Health and Care Research
Thousands with cancer-causing condition offered life-saving screening
The NHS is offering routine preventative bowel cancer screening to thousands of people in England with a genetic condition that increases their chance of developing certain cancers. This is a world-first move by the health service to help reduce cases and identify bowel cancers earlier, when successful treatment and cure is more likely. As part of the NHS Bowel Cancer Screening Programme, people with Lynch syndrome are now invited for bowel surveillance every two years, where they are seen by a specialist team and assessed for a colonoscopy which checks for polyps and signs of bowel cancer. Lynch syndrome is an inherited condition that
increases the risk of certain cancers, including bowel, ovarian and pancreatic, but out of 100 people with Lynch syndrome, screening prevents between 40 and 60 people from getting bowel cancer. Around 10,000 people in England are on the
Lynch syndrome register and are being invited to join Lynch surveillance, as part of the NHS bowel cancer screening programme. With many more unknowingly living with the disease, thousands of extra cancers will potentially be diagnosed and treated earlier. The routine colonoscopies will be offered at local bowel cancer screening centres, close to peoples’ homes, making it more convenient
10
www.clinicalservicesjournal.com I April 2024
for people to get tested. The health service also has a dedicated genetic testing programme for the condition and now almost all people diagnosed with bowel and endometrial cancer receive the initial test to check for Lynch syndrome – 94% on average between 2021-2023, which is up from 47% in 2019. A diagnosis for Lynch syndrome not only helps guide more personalised cancer treatment but enables their families and relatives to be offered testing too. Around 1,100 bowel cancers are caused by Lynch syndrome each year in England and it is thought that the syndrome increases the lifetime risk of developing bowel cancer by up to 80%.
Sponsored by
Book your AfPP Roadshow ticket now!
This year, the Association for Perioperative Practice (AfPP) is celebrating 60 years of supporting perioperative practitioners, with a programme of events, including the AfPP Roadshow – taking place at seven locations across the UK. The roadshow, titled: ‘The fundamentals of
practice: keeping patients and practitioners safe’ will bring together some of the perioperative sector’s most inspirational, forward-looking healthcare professionals to speak on a variety of topics, fundamental to all theatre practitioners, whatever stage they are at in their career. These key topic areas will include: Risk Management, Infection Control, Clinical Effectiveness, Patient Care and Dignity, and Mental Health and Wellbeing. The roadshow locations will include the
following: Birmingham, Millennium Point: Sat, 18 May; Exeter, University of Exeter: Sat, 22 Jun; Cardiff, Cardiff Metropolitan University: Sat, 13 Jul; London, Cavendish Conference Centre: Sat, 14 Sep; Glasgow, Sat, 5 Oct; Belfast, Sat, 9 Nov; and Leeds, Sat, 7 Dec. The full one-day event ticket price is: £15 for AfPP members and £25 for non-members. Book your ticket now by visiting:
https://www.eventbrite.com/cc/the-afpp- roadshow-2935759
New immunotherapy to be offered by NHS
The NHS will roll out a new immunotherapy that could offer women with advanced endometrial cancer significant extra time before their disease progresses, compared with standard chemotherapy alone. Trials have shown that adding dostarlimab (Jemperli) to chemotherapy can slow the spread of certain forms of endometrial cancer, giving patients the hope of more time to live well before their condition worsens. The NHS will begin offering the treatment,
following approval by the National Institute for Health and Care Excellence (NICE), and it is estimated that around 150-200 women living with advanced primary or recurrent endometrial cancer will be eligible each year. Clinical trials showed that nearly two thirds (64%)
of patients treated with dostarlimab alongside standard chemotherapy had not seen their cancer progress after 12 months of treatment, more than twice the rate seen in patients treated with chemotherapy alone (24%).
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88
